Overview
The product name specifies no DAC, a critical distinction from the long-acting CJC-1295 tested in landmark human studies. The dispensing pharmacy should confirm the exact GHRH-analog identity, not rely on the trade-style name alone3,5.
Pairing a GHRH analog with a ghrelin-receptor agonist offers a mechanistic reason for study. It does not demonstrate that this formulation creates natural pulses, improves sleep or changes body composition in patients1,2,3.
Why DAC matters
CJC development attached an albumin-binding group to a modified GHRH analog to extend exposure. The original chemistry and pharmacology paper expressly concerns that albumin-associated molecule5.
Ipamorelin was developed through a separate secretagogue program. Combining the classes is a new formulation question, and removing DAC prevents the long-acting CJC pharmacokinetic results from being applied directly1,5.
Mechanism of action
The GHRH-associated component and ipamorelin use different receptor pathways feeding into endogenous GH release. Human ipamorelin infusion research established a discrete hormone response1,2.
DAC-containing CJC increased GH and IGF-I while preserving pulsatility in human research, but elevated trough GH was important. Those findings do not demonstrate that this short-acting combination has the same pattern or clinical effect3,4.
- 1Signals the pituitary to release GHThe CJC-1295 component is a GHRH analog. It acts on GHRH receptors on pituitary somatotrophs, the same pathway the hypothalamus uses to trigger each natural GH pulse3,4.
- 2Amplifies the pulse through a second receptorIpamorelin activates the ghrelin receptor (GHSR-1a), a separate GH-release pathway, producing a single, discrete GH peak at 0.67 hours in healthy men1,2.
- 3Keeps stress hormones flatIn swine, ipamorelin did not raise ACTH or cortisol beyond GHRH-like levels, even at doses more than 200-fold above its GH-releasing dose1.
- 4Preserves the natural rhythmWithout the albumin-binding DAC, the GHRH analog is short-acting, and research on GHRH-analog stimulation found that the body’s pulsatile GH pattern persists4,5.
- GHRH receptor
- GHSR-1a
- Pituitary somatotrophs
- GH secretion
- IGF-I axis
What the human studies actually tested
The CJC trial found a 2–10-fold mean GH increase and a 1.5–3-fold IGF-I increase after the DAC-containing preparation. These figures are displayed only as component-class context and must not be read as a blend effect3.
The human ipamorelin study measured intravenous pharmacokinetics and GH response, including an approximately 2-hour terminal half-life. Neither it nor the DAC trial tested the exact no-DAC blend in this catalog2,3.
Two complementary GH signals1,3
GHRH-receptor and ghrelin-receptor agonists act through separate pituitary pathways, the pharmacological rationale for pairing them.
Clean, measurable GH release2
In healthy men, ipamorelin produced a single GH peak at 0.67 hours with a short 2-hour terminal half-life.
Selective by design1
Ipamorelin released GH without significant ACTH or cortisol release in swine, the selectivity that made it the first selective GH secretagogue.
Component rationale
The CJC development experiment studied albumin bioconjugation in rats and pituitary-cell assays. Ipamorelin pharmacology examined endocrine selectivity in animal systems1,5.
These experiments support studying complementary inputs, but do not identify an optimal clinical ratio or prove improved recovery. The weakest-link tier reflects the unvalidated no-DAC component and formulation rather than borrowing the stronger DAC-human tier1,5,6.
Endocrine & formulation safety
FDA notes CJC-associated serious events including increased heart rate and systemic vasodilation, alongside immunogenicity and impurity concerns. It also identifies major safety gaps for ipamorelin, including other injection routes6.
Stimulating the GH axis requires review of glucose, pituitary disease, growth-factor concerns and concomitant drugs. Blending does not remove component risks, and no combination trial establishes a safer exposure profile6.
- Confirm the no-DAC component’s exact identity with the dispensing pharmacy.
- DAC trial efficacy and half-life do not apply to this no-DAC blend.
- FDA reports CJC-associated heart-rate and vasodilatory events and component safety uncertainties [6].
- Review glucose, endocrine disease, malignancy history and medicines with your provider.
Supply, storage & administration
Landmark CJC human studies used a subcutaneous DAC-containing preparation, whereas ipamorelin pharmacokinetics were studied intravenously2,3. Neither defines an established regimen for this no-DAC vial; verify the prescribed route and whether the pharmacy supplies powder or liquid.
The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe7. Dosing is set by your provider.
Questions
Why combine it with ipamorelin?
The proposed rationale is stimulation through different GH-axis receptor pathways. Clinical benefit or synergy of this exact formulation remains unestablished.
Does the CJC half-life apply?
No. Landmark long-acting results describe the DAC-containing albumin-binding molecule.
Is it better than ipamorelin alone?
No cited controlled trial establishes that comparison for this blend.
Does it preserve natural pulses?
DAC research observed preserved pulsatility with higher trough GH, but this cannot establish the pattern of the no-DAC blend.
Can the displayed hormone increases be expected?
No. They belong to DAC-containing CJC experiments, not this formulation or an individual treatment prediction.
References
- 1.Animal study
Ipamorelin, the first selective growth hormone secretagogue. (opens in a new tab)
Raun K, Hansen BS, Johansen NL, et al.. European journal of endocrinology, 1998. PMID 9849822
Ipamorelin animal pharmacology demonstrated GH release and relative endocrine selectivity.
- 2.Human study
Gobburu JV, Agersø H, Jusko WJ, et al.. Pharmaceutical research, 1999. PMID 10496658
Intravenous ipamorelin in healthy volunteers had an approximately 2-hour terminal half-life with measured GH release.
- 3.Randomized trial
Teichman SL, Neale A, Lawrence B, et al.. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683
In healthy adults, the long-acting DAC form of CJC-1295 raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold.
- 4.Human study
Ionescu M, Frohman LA. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654
Continuous stimulation with CJC-1295 (DAC) preserved pulsatile GH secretion while raising trough GH 7.5-fold, mean GH 46% and IGF-I 45%.
- 5.Animal study
Jetté L, Léger R, Thibaudeau K, et al.. Endocrinology, 2005. PMID 15817669
Albumin-bioconjugation work identified the DAC-containing long-acting CJC molecule.
- 6.Guidance / label
U.S. Food and Drug Administration. Regulatory guidance / prescribing information, 2026.
FDA describes limited human safety information and relevant compounding risks for CJC-1295 and ipamorelin acetate.
- 7.Guidance / label
Preventing Unsafe Injection Practices (opens in a new tab)
Centers for Disease Control and Prevention. Regulatory guidance / prescribing information, 2024.
Use aseptic technique and a new sterile needle and syringe; opened multi-dose vials generally have a 28-day discard window unless the manufacturer specifies otherwise, never beyond original expiration.
Research summaries are educational and describe published studies, many in animal or cell models. They are not claims that this product treats any condition. Compounded medications are prepared by a licensed 503A pharmacy for individual patients and are not FDA-approved. Statements on this site have not been evaluated by the FDA. Products are dispensed only after review by a licensed provider. This site does not provide medical advice; talk to your provider before starting any therapy.